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Insulin resistance is a complex metabolic disorder implicated in the development of many 
chronic diseases. While it is generally accepted that body mass loss should be the primary 
approach for the management of insulin-resistance related disorders in overweight and obese 
individuals, there is no consensus among researchers regarding optimal protein intake during 







































































































































4dietary restriction. Recently, it has been suggested that increased plasma branched-chain amino 
acid (BCAAs) concentrations are associated with the development of insulin resistance and 
T2D. The exact mechanism by which excessive amino acid availability may contribute to 
insulin resistance has not been fully investigated. However, it has been hypothesised that 
mammalian target of rapamycin complex 1 (mTORC1) hyperactivation in the presence of 
amino acid overload contributes to reduced insulin-stimulated glucose uptake due to insulin 
receptor substrate (IRS) degradation and reduced Akt-AS160 activity. In addition, the long-
term effects of high-protein diets on insulin sensitivity during both weight stable and weight 
loss conditions require more research.  This review focusses on the effects of high-protein diets 
on insulin sensitivity and discusses the potential mechanisms by which dietary amino acids can 
affect insulin signaling. 
Novelty bullets: Excess amino acids may over-activate mTOR, resulting in desensitisation of 
IRS-1 and reduced insulin-mediated glucose uptake.
Keywords:  Type 2 diabetes, insulin resistance, mTOR/S6K1, high-protein diet, branched-
chain amino acids.
Introduction
Dietary protein has a central role within a healthy eating pattern, as evidenced by the fact that 
protein is the only macronutrient often represented on educational food guides (e.g., USDA’s 







































































































































5MyPlate) and that a minimal amount in the diet in necessary for meeting the body’s growth 
and regenerative requirements (National Academy of Sciences. The Institute of Medicine. 
Food and Nutrition Board 2005). Moreover, the protein content of foods is often a 
consideration of consumers when shopping at grocery markets (Li and Dando 2019). As such, 
it is crucial to not only consider the health benefits of eating a higher proportion of total daily 
energy intake from protein, but also consider the potential negative consequences on disease 
risk. From a clinical perspective, Type 2 diabetes (T2D) prevalence is predicted to reach 6.1% 
of the world’s population by 2025 (Stumvoll et al. 2005) thus placing a major socio-economic 
burden on health care systems for decades to come. Indeed, T2D is a multifactorial disease 
characterised by impaired β-cell function, reduced insulin sensitivity, and increased hepatic 
glucose production (Kahn et al. 2014). There are a number of suggested causes of insulin 
resistance in skeletal muscle; including hyperinsulinaemia, hyperglycaemia & hyperlipidemia, 
all of which have been shown to decrease Akt protein activity and induce some form of 
hyperglycaemia (Chalkley et al. 1998; Frühbeck et al. 2001; Tremblay et al. 2001; Gonzalez-
Castillo et al. 2015). The resulting hyperglycaemia increases the risk of secondary 
complications, including macrovascular and microvascular diseases (Stumvoll et al. 2005). 
One of the most important lifestyle factors in controlling and preventing T2D is dietary 
manipulation. Many different protein centric diets have been proposed to improve metabolic 
health, such as diets high in protein content (>30% of total energy intake) and low in 
carbohydrates. The popularity of controversial high-protein diets, such as Zone and Atkins 
diets, has revealed that high-protein diets may beneficially affect body composition (i.e., higher 
ratio of lean body mass to fat mass) and weight management by leading to a greater overall 
body weight loss (Anton et al. 2017). Moreover, high-protein diets have been advocated as an 
effective dietary intervention to improve insulin sensitivity. While the effect of carbohydrates 
and fats on glucose metabolism has been thoroughly investigated over the past three decades 







































































































































6(Hollenbeck and Coulston 1991; Kodama et al. 2009; Jung and Choi 2017), the role of dietary 
proteins on glucose homeostasis and insulin sensitivity is yet to be established . Overall results 
from several meta-analyses and systematic reviews have indicated that the effect of acute or 
chronic high-protein diet on insulin resistance remains inconclusive (Ajala et al. 2013; Dong 
et al. 2013; Schwingshackl and Hoffmann 2013; Yu et al. 2019).  Moreover, in the long term, 
high-protein diets are thought to be linked to insulin resistance and increased risk of 
cardiovascular diseases and cancer (Song et al. 2004). Sluijs et al. (2010) concluded, based on 
self-reported dietary assessments, that replacing 5 energy % from carbohydrate or fat with 5 
energy % from protein increases diabetes risk by ~30%, but it was left unclear if the potential 
harmful effects were due to the protein content or other nutrients within the protein meals, such 
as iron. On the other hand, the Nurses’ Health Study suggested that diets high in protein and 
fat from plant sources were associated with modestly reduced risk of T2D, when compared to 
animal sources (Halton et al. 2008). Clearly observational data and intervention studies do not 
reach the same conclusion. It is not clear whether high-protein diets are harmful, neutral, or 
beneficial for people with T2D. Therefore, this review will explore the mechanisms by which 
dietary proteins and amino acids affect insulin resistance and glucose homeostasis, and discuss 
short-term and long-term effects from physiological and controlled studies.  
High-protein diet and metabolic health
The phrase ‘high-protein diet’ can often be difficult to interpret as there is no standardized diet 
definition and simply refers to an eating pattern that emphasizes the consumption of protein 
dense foods (e.g.,  ≥1.0 g protein/kg/d or the upper range of the Acceptable Macronutrient 
Distribution Range at ≥20-35% of total daily energy intake from protein; see Table 1). 
Moreover, the term ‘protein’ in itself is non-descriptive and does not take into account that not 
all protein foods are created equal in terms of their ability to supply dietary requirements of 
essential amino acids (e.g., protein quality) (Phillips et al. 2015) or the energy intake required 







































































































































7to meet the minimal essential amino acid requirement  from various protein foods. Specifically, 
the ingestion of animal-based proteins are more efficient to achieve dietary essential amino 
acid requirement without the excessive ingestion of non-protein calories (Wolfe et al. 2018). 
In addition, animal products also vary in terms of their food matrices (nutrient-nutrient 
interactions), cooking preparation (grilled or deep fried, for example), home cooked vs. fast 
food, each of which can be manipulated to induce drastically different metabolic effects despite 
all falling under the same general umbrella of a high-protein diet. For example, on the other 
hand, plant-based protein sources, such as pulses or nuts, are also high in fibre and 
phytonutrients that may improve parameters of insulin sensitivity by themselves (Kim et al. 
2017; Clark et al. 2018; Weickert and Pfeiffer 2018). The fat content of a plant or animal based 
protein diet could also influence insulin sensitivity, as it known that n-6 polyunsaturated fats- 
the predominant dietary fatty acid being linoleic acid, and saturated fats, such as palmitic acid, 
have divergent effects on insulin sensitivity (Summers et al. 2002; Bjermo et al. 2012). In 
summary, there are many factors that need to be considered when evaluating the effects of a 
high protein diet on tissue insulin sensitivity. In the next sections we will review the acute and 
long-term effect of high protein studied in the human literature. 
Nonetheless, a number of studies have demonstrated key beneficial effects of eating a higher 
proportion of total daily energy intake from dietary protein, including fat mass loss coupled 
with lean mass retention and improved satiety, during energy restriction (Halton and Hu 2004; 
Anton et al. 2017). Body mass loss is attributed to a higher satiety, preservation of resting 
metabolic rate, and perhaps even contribution from a greater thermic effect of high-protein 
diet compared with low-protein diet (Halton and Hu 2004). Diet-induced thermogenesis is 
related to the energy required for the intestinal absorption, metabolism, and food storage 
during the postprandial period. Hence, a high-protein diet exerts a larger effect on energy 
expenditure (23-30%) compared with carbohydrates (5%-10%) and lipids (2%-3%) (Nair et 







































































































































8al. 1983). This is thought to be explained by the high adenosine triphosphate (ATP) cost for 
protein synthesis, amino acid oxidation, and urea production (Robinson et al. 1990). 
Additionally, high-protein diets are linked to increased secretion of incretin peptides, such as 
glucagon-like peptide 1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) 
which play an important role in postprandial insulin response (Fehse et al. 2005). Rizi et al. 
(2018) reported that a high protein (51.4 % energy from protein) compared to a high 
carbohydrate meal induced a significantly lower postprandial response in ghrelin 
concentration and higher in GLP-1, which was maintained significantly higher 6 hours after 
the meal intake. This suggests that an increase in protein density of the meal will promote 
greater satiety throughout the postprandial period. These key incretins potentiate glucose 
disposal by increasing insulin secretion from β-cells. GLP-1 also inhibits gastrointestinal 
motility and secretion thus augmenting satiety (Edholm et al. 2010). Other studies have shown 
that ingesting a protein-rich meal also increases GLP-1 and insulin levels leading to reduced 
postprandial hyperglycaemia and increased satiety (Blom et al. 2006; Akhavan et al. 2014). 
Numerous studies have shown that high-protein diets may also help to preserve lean body 
mass during weight loss in overweight and/or obese and T2D individuals (Larsen et al. 2010; 
Pignone 2011; Tang et al. 2013) and correct accelerated protein catabolism (Gougeon et al. 
2000; Bell et al. 2006). Hence, it is important to focus on ‘high quality‘ weight loss, which is 
aimed at maintaining adequate skeletal muscle mass with a higher ratio of fat mass loss to 
ensure long-term weight management and physical performance.
Branched-chain amino acids and insulin resistance
Certain dietary proteins are more effective at providing target amounts of essential amino acids 
into circulation than others (animal based > plant based), especially the branched chain amino 







































































































































9acids (BCAAs). BCAAs, which include leucine, isoleucine, and valine, are oxidised in 
peripheral tissues, mainly in skeletal muscle, and have diverse physiological and metabolic 
roles. In addition to their role as substrates for protein synthesis, BCAAs also act as anabolic 
signalling molecules, which are involved in signal transduction pathways essential in the 
regulation of protein synthesis and gene transcription (Dennis et al. 2011). Moreover, BCAAs 
are involved in lipolysis, lipogenesis, glucose metabolism and glucose transportation (Zhang 
et al. 2017).
 BCAAs have emerged as a dietary component of interest in the development of insulin 
resistance due to their association with both insulin resistance and T2D (Nie et al. 2018). For 
example, Newgard et al. (2009) study, using metabolomic approach, reported that obese people 
have increased catabolism of BCAAs, when compared to healthy weight controls, that was 
associated with insulin resistance. Similar findings were also reported in a cross-sectional study 
of subjects with metabolic syndrome (Huffman et al. 2009) and in cohorts of Chinese and 
Asian-Indian men (Tai et al. 2010). Wang et al. (2011) reported that increased baseline plasma 
concentrations of BCAA and aromatic amino acids such as phenylalanine, tyrosine and 
tryptophan were associated with a higher chance of developing diabetes in the future. Likewise, 
systematic review and meta-analysis summarised current metabolomic studies and concluded 
that not only BCAA and aromatic amino acids are elevated in pre-diabetics and diabetics, but 
it is also suggested that elevated plasma BCAA concentrations are linked to higher risk of 
developing T2D (Guasch-Ferré et al. 2016), which could potentially be used as novel 
biomarkers. However, not all studies have shown that elevated plasma BCAA profiles are 
reliable predictors of T2D (Kouw et al. 2015) or insulin resistance (Beals et al. 2016, 2018). 
Moreover, habitual physical activity levels should be considered when evaluting the impact of 
blood BCAA concentrations and their link to disease risk.  








































































































































While many clinical measures have been implicated as risk factors for T2D, including 
inflammatory cytokines, blood lipids and obesity, it is not known whether elevated plasma 
BCAAs are related to these factors. Wang-Sattler et al. (2012) demonstrated that elevated 
BCAAs were predictive for T2D even after adjustment for BMI, physical activity, smoking 
and HDL cholesterol, indicating that BCAAs may contribute to insulin resistance. Conversely, 
Mahendran et al. (2017) suggested that high plasma BCAAs concentrations have no causal 
effect on insulin resistance and that it is the insulin resistance that is a causal factor for increased 
circulating fasting BCAA concentrations. However, this study was completed using 
associations between genetic risk scores calculated from fasting insulin levels and genetic 
variants associated with BCAA levels, without a detailed mechanism that may explain the link 
between the two. Furthermore, it has been reported that BCAAs clearance (Marchesini et al. 
1991) and branched-chained alpha-keto acid dehydrogenase complex (BCKDC) activity are 
decreased in people with T2D (Adams 2011). BCKDC catalyses an irreversible step in the 
catabolism of BCAAs to their respective ketoacids. BCKDC is inhibited by branched-chain α-
ketoacid dehydrogenase kinase (BCKDK) and activated by the mitochondrial isoform of 
protein phosphatase 1K. The activity and the expression of these enzymes are affected in the 
obese and insulin resistance state thus contributing the BCAAs dysmetabolism (Bajotto et al. 
2009). 
Karusheva et al suggested that postprandial insulin sensitivity was improved during a 4 week 
intervention study, where the participants were randomly assigned to either have all BCAA or 
none in alternate weeks, as measured by mixed meal tolerance test but not during 
hypeinsulinemic-euglycaemic clamp, which suggests that whole body insulin sensitivity was 
not affected (Karusheva et al. 2019). In support of this, 20g of BCAA for 4 weeks did not 
change insulin concentrations of people with prediabetes (Woo et al. 2019). Therefore, large 
differences in BCAA concentration might be required to meaningfully alter insulin sensitivity. 








































































































































It is not clear whether diet itself can induce the marked changes in BCAA even observed in 
these studies. Similarly, chronic consumption of whey does not increase circulating BCAA in 
an 8-week weight loss trial (Piccolo et al. 2015), and neither did self-reported reduced or 
increased dairy protein did not change circulating free AA, including BCAA concentrations 
after a month (Prodhan et al. 2018). Weight loss itself alters the circulating amino acid profile, 
which is an added confounding factor (Tochikubo et al. 2016). Therefore, it is possible that 
while protein foods can increase BCAA acutely, but this effect does not persist over time.
Despite the evidence of elevated BCAAs level in obese and diabetic individuals, it is still not 
well understood whether high plasma BCAA concentrations are causally implicated in T2D or 
whether it is a consequence of pathophysiology of the disease. In summary, it is possible that 
increased level of BCAAs in the insulin-resistant state is a consequence of altered appearance 
and disappearance rate of BCAAs that is coupled with decreased activity of catabolic enzymes. 
Nevertheless, it has been proposed that high-protein diet, rich in BCAAs, can contribute to 
insulin resistance via hyperactivation of mammalian target of rapamycin or mechanistic target 
of rapamycin (mTOR, also known as RAPT, FRAP, RAFT) (Um et al. 2004). This is discussed 
in the following sections. 
The role of mTOR in insulin signalling
mTOR is a highly conserved Ser/Thr protein kinase that is a central regulator of various cellular 
processes, such as cellular metabolism, cell growth and proliferation, protein synthesis, 
transcription and autophagy (Dobashi et al. 2011). mTOR is inhibited by rapamycin, which is 
known to induce anti-proliferative and immunosuppressive activities in cells (Visner et al. 
2003; Janes and Fruman 2009). mTOR integrates the input of upstream pathways, such as 
insulin, growth factors IGF-1, IGF-2 and amino acids. mTOR assembles into two multi-
component complexes: mTOR complex 1 (mTORC1) and mTOR complex 2 (mTORC2). 








































































































































mTORC2 is less sensitive to rapamycin and its stimulus is not well understood as only growth 
factors have been shown to induce mTORC2 activity. On the other hand, there is a greater 
understanding about the function of mTORC1 as it is nutrient sensitive. mTORC1 integrates 
several intracellular and extracellular signals and plays a key role in the activation of protein 
translation (Dobashi et al. 2011).
The role of mTORC1 in activating and regulating insulin signalling has been comprehensively 
investigated. Insulin signalling in skeletal muscle is initiated following binding of the insulin 
to insulin receptor (IR) that then binds to IR substrate (IRS-1/2). IR is a heterotetrametic 
bifunctional complex that belongs to the receptor tyrosine kinase superfamily and consists of 
two extracellular α and two transmembrane β subunits with tyrosine kinase activity (Knudsen 
et al. 2011). Insulin binding to IR stimulates structural changes to the α subunit that leads to 
autophosphorylation of a tyrosine kinase. Tyrosine phosphorylation leads to IRS-1 and -2 
proteins interacting with the p85-regulatory subunit of phosphoinositide-dependent protein 
kinase-1 (PI3K). Activation of this enzyme results in the activation of the p110 catalytic 
subunit of PI3K and production of the second lipid messenger phosphatidylinositol-3,4,5-
triphosphate (PIP3). PIP3 then binds to the pleckstrin homology domain of Akt [Also known as 
protein kinase B (PKB)] (Mackenzie and Elliott 2014). Akt is a serine/threonine-specific 
protein kinase that plays a key role in multiple cellular processes, such as cell growth, 
proliferation, apoptosis, cell migration and glucose metabolism. There are three homologous 
isoforms of Akt that have been identified – Akt1/PKBα, Akt2/PKBβ and Akt3/PKBγ (Manning 
and Toker 2017). Among these isoforms, Akt2 plays a central role in insulin-stimulated glucose 
uptake in muscle tissues. Binding of PIP3 to Akt results in conformational change in Akt that 
is then followed by its phosphorylation at Thr308 by PDK1, inducing about 10% of the kinase 
activity (Manning and Toker 2017). Subsequently this leads to phosphorylation of specific 
serine residue (Ser473) of the carboxyl-terminal hydrophobic motif of Akt by mTORC1 (Wick 








































































































































et al. 2000) (Fig. 1). This promotes full Akt activation and its translocation to the cytoplasm, 
mitochondria and nucleus where it phosphorylates its many substrates. Akt substrate 160 
(AS160) is thought to be the most important signalling molecule for glucose uptake. Upon 
activation, AS160 is phosphorylated at Thr642 by Akt leading to reduction in Rab GTPase-
activating proteins (Rab-GAP) activity and promoting glucose transporter-4 (GLUT4) 
translocation (Sakamoto and Holman 2008; Naufahu et al. 2018). GLUT4 is a glucose 
transporter containing 12-transmembrane domains, that is sequestered into specialised 
intracellular compartments known as GLUT4 storage vesicles (GSVs) in unstimulated cells. In 
response to insulin stimulation, GLUT4s are translocated from GSVs to the plasma membrane 
via targeted exocytosis to facilitate glucose uptake in muscle and fat tissue.
Amino acids and insulin resistance: proposed mechanisms
Dietary protein derived amino acids, primarily leucine, are potent activators of mTORC1 
(Kimball et al. 2016; Son et al. 2019). Indeed, most of the evidence on the interaction between 
elevated postprandial dietary amino acid availability in circulation (or intracellularly) and the 
regulation of mTORC1 activation is based on free amino acid ingestion and/or isolated protein 
sources (Van Vliet et al. 2019). These methods usually lead to a rapid and transient pattern of 
aminoacidemia; neither of which are indicative of postprandial blood amino acid profiles after 
the ingestion of mixed meals or protein dense food sources (e.g., chicken, eggs, beef). In our 
hands, meal combinations and/or the ingestion of protein dense foods do not elicit such strong 
activation of mTORC1 or associated downstream targets (i.e., p70S6K or 4E-BP1) (Beals et 
al. 2016; Sawan et al. 2018; Van Vliet et al. 2018; Van Vliet et al. 2019). In any case, based on 
in vitro culture models, intracellular amino acid availability regulates mTORC1 via the RAS-
related GTP-binding protein (Rag) family of small GTPases: RagA, RagB (RagA/RagB) and 
Rag C, Rag D (RagC/RagD) (Zoncu et al. 2011; Han et al. 2012). In the presence of amino 
acids, regulator complex and vacuolar H+ adenosine triphosphatase (v-ATPase) undergo 








































































































































conformational change resulting in stimulation of guanine nucleotide exchange factor (GEF) 
(Willoughby 2015). GEF promotes GTP-nucleotide charging that activates Rag proteins 
resulting in the recruitment of mTORC1 to the lysosomal surface where mTORC1is activated 
by Rheb (Kim et al. 2013). Activation of mTORC1 by amino acids is essential for many cellular 
functions, including anabolic process, cell growth and proliferation (Fig. 1). However, it has 
been hypothesised that mTORC1 hyperactivation, stimulated under non-physiological amino 
acid overload may contribute to insulin resistance (Hay and Sonenberg 2004; Um et al. 2004; 
Tzatsos and Kandror 2006).  In vitro studies have shown that chronic activation of the 
mTOR/S6K1 pathway by amino acids can promote insulin resistance in muscle cells via 
increased IRS-1 Ser307 phosphorylation and degradation thus leading to the impairment of PI3K 
stimulation (Haruta et al. 2000; Tremblay and Marette 2001) (Fig. 1). PI3K is a key effector in 
insulin’s metabolic action via the downstream activation of Akt, which is essential for GLUT4 
translocation and glucose uptake. In addition, Um and colleagues reported that hyperactivation 
of mTORC1 has been shown to drive S6K1-mediated feedback inhibition of insulin signaling, 
thus reducing glucose uptake in skeletal muscles of obese rodents (Um et al. 2004).  Other 
studies conducted in myotubes and isolated rat skeletal muscles also suggest that leucine may 
interfere with insulin signaling, given that leucine stimulates mTOR/S6K1 and IRS-1 Ser307 
phosphorylation (Tzatsos and Kandror 2006; Iwanaka et al. 2010). Collectively, this research 
suggests that over-activation of mTORC1 due to amino acid availability may contribute to 
insulin resistance in muscle. In contrast some research supports an opposing hypothesis that 
leucine improves insulin sensitivity and glucose control. Macotela et al. (2011) demonstrated 
that mice fed a high-fat diet showed that, serine phosphorylation of IRS-1 was reduced, despite 
an increase in phosphorylation of S6K1, with chronic leucine supplementation for 8 weeks. In 
addition, leucine supplementation correlated with improved insulin sensitivity, a finding that 
is consistent with studies of obese rodents (Guo et al. 2010; Eller et al. 2013; Li et al. 2013). 








































































































































The differences in study design, including the metabolic phenotypes of obese rodents and 
protein supplementation dose and type, may explain some of the inconsistencies. While amino 
acids are potent activators of mTORC1, some suggest that amino acid associated activation of 
mTOR may not be sufficient to induce insulin resistance (Houde et al. 2010; Li et al. 2013). It 
is possible that BCAAs may elicit different effects on glucose homeostasis, depending on the 
prevalence of anabolic and catabolic states of the organism (positive or negative energy 
balance) and thus making it difficult to determine the exact effect of BCAAs on insulin 
signalling (Bifari and Nisoli 2017). Further detailed work examining amino acids and insulin 
resistance is required to determine key mechanistic pathways explaining the role of high-
protein diet on glucose homeostasis. 
Human studies examining the role of mTOR/S6K1 pathway in T2D are very limited. 
Bandyopadhyay et al. (2005) reported that people with T2D have greater basal phosphorylation 
of IRS-1 at Ser307 that corresponded with lower insulin-stimulated IRS-1 tyrosine 
phosphorylation. Additionally, this study found that diabetics and obese individuals had lower 
PI3K and Akt activity compared with healthy participants. Similar findings were also reported 
in studies with prediabetics (Storgaard et al. 2001) and people with T2D (Kim et al. 1999; 
Krook et al. 2000; Karlsson et al. 2005). However, studies examining the effect of amino acids 
on mTOR/Akt and insulin resistance in human participants report inconsistent results. The 
effects of amino acids were shown to be associated with inhibitory phosphorylation of IRS-1 
and inactivation of PI3K in healthy human participants (Tzatsos and Kandror 2006). Tremblay 
et al. (2005) studied healthy men and found that intravenous (IV) infusion of amino acids 
decreased insulin-stimulated glucose disposal, which the authors attributed to elevated IRS-
1Ser312 phosphorylation and blunted PI3K, while failing to increase insulin-induced 
phosphorylation of Akt. Conversely, Bassil et al. (2011) investigated the effects of a 
hyperinsulinaemic-hyperglycaemic clamp, starting with postabsorptive amino acid 








































































































































concentration then followed by infusion of amino acids matching postprandial concentration 
in T2D individuals. This work showed that infusion of amino acids increased phosphorylation 
of AktSer473, AktThr308 and mTORSer2448, yet no changes were observed in the phosphorylation 
of IRS-1Ser636/639 and IRS-1Ser1101. Additionally, no changes were observed in glucose infusion 
rates, glucose disposal or in endogenous glucose production with IV amino acid infusion, 
suggesting that amino acid availability does not alter whole-body glucose control. Yet, with 
the oral ingestion of leucine and whey proteins, Smith et al. (2016) showed that the positive 
effects of a weight loss diet with normal protein intake were blunted by an increase in protein 
intake, in obese, postmenopausal women. This was reflected in the decrease in glucose disposal 
and phosphorylation of AktSer473 when compared to the normal protein diet group. Such a 
finding is not consistent with the finding that there are no differences in postprandial muscle 
protein synthesis rates, an mTORC1 mediated event, after the ingestion of a meal-like amount 
of dietary protein between T2D patients vs. normoglycemic controls (Kouw et al. 2015). Taken 
together, these data suggest that excessive amino acids availability may contribute to insulin 
resistance via mechanisms yet to be determined, in humans with similar metabolic 
characteristics. 
The effect of short and long-term high-protein diets on insulin resistance
The synergistically stimulating effect of protein and carbohydrate co-ingestion on insulin 
concentration in healthy adults was first reported in the 1960s (Rabinowitz et al. 1966; Pallotta 
and Kennedy 1968). Van Loon et al. (2003) demonstrated that amino acid ingestion with 
carbohydrates increased plasma insulin response 2-3-fold in patients with T2D. While an 
increase in the insulin concentration is itself sufficient to cause insulin resistance, this effect 
requires prolonged hyperinsulinemia (Del Prato et al. 1994).  








































































































































However, studies examining long-term effect of high protein diets during energy restriction 
have reported a variety of beneficial effects, including medication reduction, better adherence 
and improvements in haemoglobin A1c (HbA1c) (Table 1). Most of the studies that have 
examined the effect of increasing dietary protein have done so in the context of energy 
restriction. While weight loss itself can improve insulin sensitivity, comparisons with the 
control group (provided that weight loss was matched) can provide insight into the metabolic 
effect of high protein on insulin sensitivity. In obese participants, energy restriction and high-
protein diet have been shown to be more effective in reducing insulin resistance when 
compared to low protein diet (Farnsworth et al. 2003; Claessens et al. 2009; De Luis et al. 
2015; Mateo-Gallego et al. 2017). On the other hand, some studies suggested that there are no 
differences between high-carbohydrate and high-protein diets (34% from total energy derived 
from protein and respectively 1.34 g protein/kg of body weight/day), and beneficial outcomes 
for insulin sensitivity are attributed to body mass reduction (Noakes et al. 2005; Campos-
Nonato et al. 2017). In contrast, Smith et al. (2016) reported that a high-protein diet (1.2 g 
protein/kg of body weight/day) may blunt beneficial effects of weight loss and prevent 
improvements in muscle insulin signalling through adverse effects on the metabolic pathways 
involved in oxidative stress, without any changes in p-mTORSer2448 or p-AMPKThr172 in muscle. 
Similar disagreements about high-protein diet effect on insulin sensitivity are evident in studies 
with diabetic participants. While Sargrad et al. (2005) reported no effect of high-protein diets 
on fasting insulin and glucose levels,  Gannon et al. (2003) demonstrated that high-protein diet 
decreased HbA1c after 5 weeks, with no associated weight change during the study. The 
discrepancy may be due to the fact that protein may primarily affect postprandial insulin and 
glucose concentrations. It is also worth noting that all the foods within this study were provided 
by the researchers for the duration of the intervention, which is likely to have increased 
compliance to dietary protocol. Research that incorporated energy restriction during high-








































































































































protein diet intervention reported a variety of beneficial outcomes, such as decreased fasting 
glucose and insulin requirements (Luger et al. 2013) as well as a reduction in HbA1c (Larsen 
et al. 2011). While high-protein diets are feasible and safe for individuals with T2D, they do 
not always provide superior long-term metabolic benefit over a standard protein intake during 
energy restriction. The inconsistent findings may be attributed to the confounding effects of 
differences in protein sources in diet (e.g. consumption of dairy and meat products versus plant 
proteins), differences in weight loss, participant characteristics, overall energy balance state 
and other lifestyle factors often cited in several systematic reviews and meta-analysis 
(Schwingshackl and Hoffmann 2013; Rietman et al. 2014). There is also the issue that many 
long-term trials, which are included within meta-analysis, lack the internal validity required to 
assess physiological efficacy, unless they provide the intervention foods/diet and/or can 
objectively assess compliance. Studies that have used oral or IV amino acids can provide 
mechanistic insight that may overcome some of these limitations, and therefore inform the 
food-based literature.
Mechanistic studies with oral or intravenous amino acids
 Manders et al. (2005) reported that co-ingestion of amino acid mixture with carbohydrates 
during hyperglycemic clamp resulted in 3-4- fold greater insulin response that improved 
postprandial glucose disposal and lowered plasma glucose concentration in patients with T2D. 
However, studies with healthy individuals reported a decrease in whole-body glucose disposal 
and greater insulin resistance in response to IV amino acid infusion during euglycaemic-
hyperinsulinemic clamp (Pisters et al. 1991; Flakoll et al. 1992; Krebs et al. 2002; Tremblay et 
al. 2005). It is important to note that during hyperinsulinemic-euglycemic clamp, insulin-
mediated decrease in amino acid concentration results in greater glucose disposal compared to 
when amino acids are maintained at their basal level, and they do not represent normal 
physiological concentration. As a result, glucose disposal during amino acid IV infusion is 








































































































































compared to a physiological condition where plasma amino acid concentrations are below the 
baseline levels. This could potentially explain a greater glucose disposal in ‘control’ compared 
to amino acid infusion. Everman et al. (2015) designed a study in which BCAAs concentrations 
were maintained in the control group in a way that was not different from baseline/ 
postabsorptive levels during insulin infusion. In this way, they were able to investigate the role 
of increased plasma BCAA concentration on glucose disposal. The study concluded that short-
term increase in plasma BCAAs does not modify insulin sensitivity of glucose metabolism.
Conclusion
Glucose homeostasis involves a complex interplay and cross-talk between pancreatic β-cells 
and insulin sensitive peripheral tissues. Amino acids are nutrient signals that can induce a 
variety of direct and indirect effects at the cellular and organismal level. Despite the potentially 
favorable effects of high protein intake, controversy exists regarding the findings from short 
(< 6 month) and long-term interventional studies and the differences in participants’ 
characteristics.  Moreover, there is a debate among nutrition experts on what the optimal 
amount of dietary protein is for those with T2D (Hamdy and Horton 2011). In contrast, it has 
been proposed that ‘excessive’ amino acids may hyperactivate the mTOR/S6K1 axis, which 
may present an inhibitory effect on insulin-mediated PI3K/IRS-1 activation, reducing insulin-
stimulated glucose uptake and increasing insulin resistance. Indeed, understanding the 
molecular basis underpinning a macro-nutrient related disease risk is relevant to have a 
complete understanding of a recommendation providing dietary guidance; however, it is also 
important to consider the experimental model is not always indicative of a healthy eating 
pattern and thus dietary context is key for accurate interpretation.  It is possible that a high-
protein diet may contribute to hyperinsulinemia, yet, as a dietary strategy, it could be helpful 
for reducing body weight and subsequently increasing insulin sensitivity. Nevertheless, there 
is a need for more research exploring the effects of high-protein diets on both plasma BCAAs 








































































































































concentrations and intracellular signaling in insulin-sensitive tissue, which could potentially 
indicate whether high BCAAs concentrations contribute to insulin resistance or are a 
consequence of the disease.
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 Table 1. Overview of high-protein diets on insulin resistance in human studies




12 weeks ≈30% restriction of total 
energy

















































































































































12 weeks ≈ 1300kcal per day









12 weeks 500kcal per day for 5 weeks 
followed by normal ad 
libidum for 7 weeks






Obese adults 9 months  1050 cal/day, 




De Luis et 
al. 2015
Obese woman 6 months Calorie restriction to induce 
10% weight loss
HP: 1.2 g protein/kg/day
↔Glucose Ra and 
Rd





6 months Caloric restriction of 500 
kcal less than the RMR 







Obese women 6 months Caloric deficit of 
600 kcal/day









5 weeks No specific energy 
restriction








8 weeks No specific energy 
restriction








12 weeks No specific energy 
restriction




Luger et al. 
2013
Abbreviations: Basal glucose rate of appearance (Ra) and glucose rate of disappearance (Rd); 
HbA1c, glycated haemoglobin; HOMA2-IR, homeostasis model assessment of insulin 
resistance index 2 to assess insulin resistance; HP, high-protein diet; iAUC, the incremental 
area under the curve; RMR, resting metabolic rate. 















































































































































































































































































Figure. 1: Potential mTOR/S6K1 signalling pathway in response to high intake of amino acids. 
These mechanisms are largely based on experimental models (e.g., in vitro and animal models) 
not commonly experienced in a healthy eating patterns such as meal combinations and protein 
dense foods.
Abbreviations: AA, amino acids; Akt, serine/threonine protein kinase; AS160, 160 kDa Akt substrate; 
GDP, Guanosine diphosphate; GEF, guanine nucleotide exchange factors; GLUT4, glucose transporter 
4; GSV, GLUT4 storage vesicle; GTP, Guanosine-5'-triphosphate;IRS, insulin receptor substrate; 
PDK1, phosphoinositide-dependent protein kinase-1; PI3K, class IA phosphatidylinositol 3-kinase; 
PIP2, phosphatidylinositol (4,5)-bisphosphate; PIP3, phosphatidylinositol 3,4,5-trisphosphate; Rab-
GAP, Rab-GTPase-activating protein; Rab-GDP, guanosine-50-diphosphate-loaded Rab;Rab-GTP, 
guanosine-50-triphosphate-loaded Rab; Rag C/D, Rag heterodimer C/D; RagA/B, Rag heterodimer 
A/B; Raptor, Regulatory-associated protein of mTOR; S6K1, ribosomal protein S6 kinase beta-1; V-
ATPase, vacuolar-type H+-ATPase.
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